Cleveland Clinic reported early Phase I results for ARO-DIMER-PA, a dimerized siRNA intended to silence PCSK9 and APOC3 in the liver using a single dose. In a cohort of 31 patients, investigators said LDL cholesterol and serum triglycerides fell substantially, with tolerability described as acceptable and adverse events minimal. The trial was conducted in partnership with Arrowhead Pharmaceuticals. The program is designed to combine two metabolic pathways linked to cardiovascular risk—LDL lowering via PCSK9 inhibition and triglyceride reduction via APOC3 suppression—into one redosable approach. If confirmed in later trials, the single-session dual-pathway concept could differentiate from existing PCSK9-targeting therapies, including antibodies and single-target RNA approaches, particularly for patients with mixed hyperlipidemia risk profiles.